Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRB | P10828 | 2/20 | 0.68 |
| ▸ | THRA | P10827 | 1/20 | 0.68 |
| ▸ | NMT1 | P30419 | 1/20 | 0.67 |
| ▸ | LPAR2 | Q9HBW0 | 2/20 | 0.66 |
| ▸ | LPAR3 | Q9UBY5 | 1/20 | 0.66 |
| ▸ | MAPT | P10636 | 4/20 | 0.64 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.64 |
| ▸ | TDP2 | O95551 | 1/20 | 0.64 |
| ▸ | GAA | P10253 | 1/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.61 |
| ▸ | LMNA | P02545 | 1/20 | 0.61 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.60 |
| ▸ | POLB | P06746 | 1/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.57 |
| ▸ | MEN1 | O00255 | 1/20 | 0.57 |
| ▸ | SRC | P12931 | 1/20 | 0.56 |
| ▸ | LPAR1 | Q92633 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7821478 | 1.00 | THRB (0.68) | THRBTHRANMT1LPAR2LPAR3 | |
| SCHEMBL2462042 | 1.00 | THRB (0.68) | THRBTHRANMT1LPAR2LPAR3 | |
| SCHEMBL22862257 | 0.91 | THRB (0.59) | THRBTHRANMT1LPAR2LPAR3 | |
| SCHEMBL13381201 | 0.86 | LPAR2 (0.70) | THRBTHRANMT1LPAR2LPAR3 | |
| SCHEMBL9359898 | 0.86 | LPAR2 (0.70) | THRBTHRANMT1LPAR2LPAR3 | |
| SCHEMBL15370243 | 0.86 | LPAR2 (0.70) | THRBTHRANMT1LPAR2LPAR3 | |
| SCHEMBL11137034 | 0.85 | LPAR2 (0.88) | THRBNMT1LPAR2LPAR3MAPT | |
| SCHEMBL11133691 | 0.85 | LPAR2 (0.88) | THRBNMT1LPAR2LPAR3MAPT | |
| SCHEMBL21702654 | 0.84 | LPAR2 (0.68) | THRBTHRANMT1LPAR2LPAR3 | |
| SCHEMBL7820872 | 0.84 | THRB (0.89) | THRBTHRANMT1LPAR2LPAR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11912831-B2 | Hydroxyethylpyrrolidone ethacrylate/glycidyl ethacrylate copolymers | ISP INVESTMENTS LLC (US) | 2024-02-27 | — | — | US | disclosed |
| CN-102639191-A | Method and composition for color modulation | UNILEVER NV | 2012-08-15 | — | — | CN | disclosed |
| EP-2367522-A2 | METHOD AND COMPOSITION FOR SKIN COLOR MODULATION | Unilever Plc, A Company Registered In England And Wales under company no. 41424 of Unilever House (GB) | 2011-09-28 | — | — | EP | disclosed |
| WO-2010072805-A2 | METHOD AND COMPOSITION FOR COLOR MODULATION | UNILEVER PLC (GB) | 2010-07-01 | — | — | WO | disclosed |
| US-20100158829-A1 | Method and Composition for Color Modulation | CONOPCO, INC., D/B/A UNILEVER (US) | 2010-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11912831-B2 | Hydroxyethylpyrrolidone ethacrylate/glycidyl ethacrylate copolymers | MMAB, PCNA, HMBS | THRB 4058/4885THRA 2438/4885NMT1 1225/4885 |
| US-20100158829-A1 | Method and Composition for Color Modulation | TYR, TH, COMT | THRB 1120/4885THRA 2019/4885NMT1 1138/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.